Vaxxinity Alzheimer’s treatment shows promising results in early trial

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Alzheimer's disease Alzheimer Clinical trial

Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).

UB-311 is a synthetic, peptide-based active immunotherapy that targets toxic beta-amyloid (Aβ) oligomers and fibrils and oligomers.

Two passive immunotherapies – monoclonal antibodies (mAbs) targeting Aβ – have recently been authorized by the FDA, validating Aβ as a target for disease-modifying immunotherapies of AD.

However, they have been associated with amyloid-related imaging abnormalities (ARIA), which can present as vasogenic edema or sulcal effusion (ARIA-E), or as hemosiderin deposits such as microhemorrhages and superficial siderosis (ARIA-H).

Furthermore, the FDA-licensed mAbs require IV infusions every two weeks, and are priced at $26,500 annually, which does not include the cost of administering them or monitoring for ARIA.

In contrast, Vaxxinity claims UB-311 has the potential to offer multiple competitive advantages, including lower rates of ARIA-E; improved convenience through less frequent dosing and ease of administration through intramuscular injection; as well as improved accessibility and cost-effectiveness.

The 78-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter, study was conducted in Taiwan.

UB-311 elicited a robust, rapid, and titrated antibody response to Aβ and was generally well-tolerated, with no cases of ARIA-E and limited cases of asymptomatic ARIA-H.

Trends of slowing disease progression were also observed across key cognitive and functional measures for UB-311-treated versus placebo-treated participants.

Mei Mei Hu, CEO of Vaxxinity, said: “This publication supports the innovative work that we and our collaborators are conducting to advance UB-311 for the potential treatment, and even prevention, of Alzheimer’s disease."

“Imagine expanding the addressable patient population of beta-amyloid immunotherapies by multiple orders of magnitude, potentially over 1,000x, and delivering life-changing medicine at a fraction of the cost. That is our vision for UB-311 and the potential power of active immunotherapies.”

Jeffrey Cummings, director for transformative neuroscience at the University of Nevada and co-author of the paper, added: “The UB-311 Phase 2a program accomplished its goals of establishing safety and tolerability, while generating high levels of anti-amyloid antibodies.”

“The gradual, natural titration of antibody titers through this approach may have contributed to a lack of ARIA-E in this study. Vaccine approaches such as UB-311 represent important ways forward in advancing treatment and prevention of Alzheimer’s disease and offer the potential to transform the treatment landscape by providing participants with an accessible therapeutic option.”

Related topics Bio Developments

Related news

Show more

Follow us